TW202506733A - 淋巴毒素β受體促效劑結合蛋白 - Google Patents

淋巴毒素β受體促效劑結合蛋白 Download PDF

Info

Publication number
TW202506733A
TW202506733A TW113121515A TW113121515A TW202506733A TW 202506733 A TW202506733 A TW 202506733A TW 113121515 A TW113121515 A TW 113121515A TW 113121515 A TW113121515 A TW 113121515A TW 202506733 A TW202506733 A TW 202506733A
Authority
TW
Taiwan
Prior art keywords
ltβr
seq
amino acid
binding protein
binding
Prior art date
Application number
TW113121515A
Other languages
English (en)
Chinese (zh)
Inventor
拉傑庫馬爾 努巴德
愛恩 納文 福爾茲
泓育 王
宮丹陽
萊恩 班傑明 凱斯
竣 張
克莉絲汀 伊蓮 汀博爾格
費南多 加瑟斯
賴勤文
Original Assignee
美商安進公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安進公司 filed Critical 美商安進公司
Publication of TW202506733A publication Critical patent/TW202506733A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW113121515A 2023-06-12 2024-06-11 淋巴毒素β受體促效劑結合蛋白 TW202506733A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363472565P 2023-06-12 2023-06-12
US63/472,565 2023-06-12

Publications (1)

Publication Number Publication Date
TW202506733A true TW202506733A (zh) 2025-02-16

Family

ID=91899198

Family Applications (1)

Application Number Title Priority Date Filing Date
TW113121515A TW202506733A (zh) 2023-06-12 2024-06-11 淋巴毒素β受體促效劑結合蛋白

Country Status (14)

Country Link
EP (1) EP4724490A2 (fr)
KR (1) KR20260025131A (fr)
CN (1) CN121399157A (fr)
AR (1) AR132931A1 (fr)
AU (1) AU2024305352A1 (fr)
CL (1) CL2025003919A1 (fr)
CO (1) CO2025018800A2 (fr)
IL (1) IL325097A (fr)
JO (1) JOP20250305A1 (fr)
MX (1) MX2025015224A (fr)
PE (1) PE20260306A1 (fr)
TW (1) TW202506733A (fr)
UY (1) UY40783A (fr)
WO (1) WO2024258870A2 (fr)

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7183388B2 (en) 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CA2494310A1 (fr) 2002-08-01 2004-02-12 Immunomedics, Inc. Anticorps anti-alpha-fetoproteine immu31, proteines de fusion et procedes d'utilisation de ceux-ci
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
NZ544797A (en) 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
WO2007005612A2 (fr) 2005-07-01 2007-01-11 Medimmune, Inc. Approche integree permettant de generer des applications therapeutiques a base de proteine multidomaine
US8017119B2 (en) 2005-12-28 2011-09-13 Daiichi Sankyo Company, Ltd. Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
NZ596295A (en) 2006-03-10 2013-01-25 Wyeth Corp Anti-5T4 antibodies and uses thereof
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
CA2682390A1 (fr) 2007-04-17 2008-10-30 Imclone Llc Inhibiteurs specifiques de pdgfr.beta.
DK2178921T3 (en) 2007-07-17 2016-04-04 Squibb & Sons Llc Monoclonal antibodies to glypican 3
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
DK2222706T4 (en) 2007-12-14 2016-11-21 Novo Nordisk As Antibodies that bind to NKG2D and its use
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
AU2009221916A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
HRP20150965T1 (hr) 2009-03-25 2015-11-06 Genentech, Inc. Anti-fgr3 protutijela i metode koje ih koriste
EP2236517A1 (fr) 2009-03-31 2010-10-06 Takara Bio, Inc. Anticorps monoclonal à fragment anti-fibronectine
CN102695750A (zh) 2009-05-21 2012-09-26 柽柳技术有限责任公司 基于藻酸盐的建筑材料
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
AU2010288469A1 (en) 2009-08-31 2012-03-01 Roche Glycart Ag Affinity-matured humanized anti CEA monoclonal antibodies
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
JP5660486B2 (ja) 2010-02-12 2015-01-28 国立大学法人 鹿児島大学 ムチン１（ｍｕｃ１）タンパク質に対する抗体及びその用途
WO2011110642A2 (fr) 2010-03-10 2011-09-15 Genmab A/S Anticorps monoclonaux contre c-met
AU2011239583A1 (en) 2010-04-15 2012-11-29 Alper Biotech, Llc Monoclonal antibodies against HER2 antigens, and uses therefor
WO2011134060A1 (fr) 2010-04-27 2011-11-03 National Research Council Of Canada Anticorps à domaine unique anti-icam-1 et leurs utilisations
WO2011139375A1 (fr) 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Anticorps dirigés contre l'anhydrase carbonique ix et méthodes et utilisations associées
EP2576620A1 (fr) 2010-05-26 2013-04-10 Regents Of The University Of Minnesota Anticorps anti-cd133 à fragments monocaténaires variables et leurs utilisations
CA3051311A1 (fr) 2010-05-27 2011-12-01 Genmab A/S Anticorps monoclonaux contre her2
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
WO2012012759A2 (fr) 2010-07-22 2012-01-26 The Regents Of The University Of California Anticorps-antigènes antitumoraux et méthodes d'utilisation correspondantes
JP5883443B2 (ja) 2010-07-22 2016-03-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規の抗原結合タンパク質
US20140093514A1 (en) 2011-06-03 2014-04-03 University Of Zurich Magea3 binding antibodies
AU2012284321C1 (en) 2011-07-15 2017-07-13 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
EP2548891A1 (fr) 2011-07-18 2013-01-23 Universiteit Maastricht Anticorps monoclonal humain contre la subunité gamma du récepteur de l'acétylcholine pour une utilisation dans le traitement du rhabdomyosarcome
KR20150082503A (ko) 2012-11-09 2015-07-15 화이자 인코포레이티드 혈소판 유래 성장 인자 b 특이적 항체, 및 그의 조성물 및 용도
ES2831374T3 (es) 2012-11-21 2021-06-08 Janssen Biotech Inc Anticuerpos de EGFR/c-Met biespecíficos
CA2893378A1 (fr) 2012-12-07 2014-06-12 Kyowa Hakko Kirin Co., Ltd. Anticorps anti-folr1
KR102489953B1 (ko) 2013-02-07 2023-01-20 씨에스엘 리미티드 Il-11r 결합 단백질 및 이의 용도
CA2902505A1 (fr) 2013-03-06 2014-09-12 Merrimack Pharmaceuticals, Inc. Anticorps bispecifiques anti-c-met a fc en tandem
US9790274B2 (en) 2013-03-14 2017-10-17 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
HUE054057T2 (hu) 2013-08-07 2021-08-30 Affimed Gmbh EGFRvIII specifikus antitest-kötõhelyek
MY178160A (en) 2014-03-11 2020-10-06 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
WO2015173249A1 (fr) 2014-05-14 2015-11-19 F. Hoffmann-La Roche Ag Protéines de liaison à l'antigène her1 se liant à l'épingle à cheveux beta de her1
KR102226248B1 (ko) 2014-06-04 2021-03-12 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
WO2016061142A1 (fr) 2014-10-14 2016-04-21 Novartis Ag Molécules d'anticorps de pd-l1 et leurs utilisations
EP3250611B1 (fr) 2015-01-26 2021-04-21 The University of Chicago Lymphocytes t à récepteur d'antigène chimérique (car) reconnaissant le récepteur il 13r-alpha2 spécifique au cancer
WO2016154623A2 (fr) 2015-03-26 2016-09-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anticorps monoclonaux anti-cd133 et compositions et méthodes associées
CA2988912C (fr) 2015-06-10 2023-09-12 National Research Council Of Canada Anticorps specifiques de l'anhydrase carbonique ix et leurs utilisations
KR20180012850A (ko) 2015-06-24 2018-02-06 유레카 쎄라퓨틱스, 인코포레이티드 Ny-eso-1 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도
CN109641954A (zh) 2016-08-29 2019-04-16 里珍纳龙药品有限公司 抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法
US10738130B2 (en) 2016-09-23 2020-08-11 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof
WO2018069871A2 (fr) 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Protéines de liaison anti-kras
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
CN107446050A (zh) 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法
BR112020005742A2 (pt) 2017-09-21 2020-10-13 Umc Utrecht Holding B.V. anticorpo anti-gd2 para o tratamento de neuroblastoma
SG11202003652QA (en) 2017-10-27 2020-05-28 Univ New York Anti-galectin-9 antibodies and uses thereof
BR112020011469A2 (pt) 2017-12-21 2020-11-24 F. Hoffmann-La Roche Ag anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
BR112020022595A2 (pt) 2018-05-23 2021-02-09 Pfizer Inc. anticorpos específicos para gucy2c e usos dos mesmos
CN119930818A (zh) 2018-06-29 2025-05-06 爱必泰生物有限公司 抗l1cam抗体及其用途
WO2020025792A1 (fr) 2018-08-03 2020-02-06 Amgen Research (Munich) Gmbh Constructions d'anticorps pour cldn18.2 et cd3
WO2020081579A1 (fr) 2018-10-15 2020-04-23 Board Of Regents, The University Of Texas System Anticorps monoclonaux dirigés contre la dickkopf3 humaine et leurs utilisations
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations

Also Published As

Publication number Publication date
AR132931A1 (es) 2025-08-13
EP4724490A2 (fr) 2026-04-15
CO2025018800A2 (es) 2026-03-26
CN121399157A (zh) 2026-01-23
IL325097A (en) 2026-02-01
WO2024258870A8 (fr) 2025-12-11
PE20260306A1 (es) 2026-02-11
UY40783A (es) 2024-12-31
MX2025015224A (es) 2026-02-03
CL2025003919A1 (es) 2026-01-23
WO2024258870A2 (fr) 2024-12-19
KR20260025131A (ko) 2026-02-23
JOP20250305A1 (ar) 2025-12-11
AU2024305352A1 (en) 2025-12-04

Similar Documents

Publication Publication Date Title
US12552877B2 (en) Anti-TL1A antibodies and uses thereof
US12435133B2 (en) Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof
US10233258B2 (en) Bispecific binding proteins that bind CD40 and mesothelin
US20210388105A1 (en) Novel anti-cd39 antibodies
CA2932515C (fr) Anticorps caninises
CN103282382B (zh) 抗il‑23抗体
US20230002489A1 (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
WO2021180205A1 (fr) Protéine de liaison à pvgrig et ses utilisations médicales
CA2977621C (fr) Nouvel anticorps se liant a la tfpi et composition le comprenant
KR20160131061A (ko) 항-mcam 항체 및 관련된 사용 방법
US20220363754A1 (en) Anti-tigit antibodies and application thereof
WO2022242758A1 (fr) Anticorps anti-cd73 et son utilisation
WO2023227033A1 (fr) Anticorps anti-bdca2 et son utilisation
JP2022500004A (ja) 抗ｃｄ４０抗体及びその使用
US20240059771A1 (en) Anti-cldn-18.2 antibody and use thereof
IL325097A (en) Lymphotoxin receptor agonist binding proteins
EP4541820A1 (fr) Anticorps monoclonal contre tfpi et son utilisation
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
JP2026513302A (ja) 抗ｉｌ－２５抗体及びその使用方法
BR112022000628B1 (pt) Anticorpo anti-tigit isolado ou fragmento de ligação ao antígeno do mesmo, moléculas de ácido nucleico isoladas, vetor recombinante ou de expressão, composição farmacêutica, combinação, usos dos mesmos, kit, artigo de manufatura, e método para detecção de tigit em uma amostra
BR122025021892A2 (pt) Células hospedeiras